新加坡高危血液病患者泊沙康唑预防治疗的真实世界经验：一项前瞻性审计。 - Suppr | 超能文献

Real-world experience with posaconazole prophylaxis in high-risk hematological patients in Singapore: a prospective audit.

作者信息

Low Chian Yong, Ong Wen Chong, Wong Evelyn, Ding Ying, Diong Colin Phipps, Jin Jing, Lim Zi Yi, Hsu Li Yang

出版信息

J Infect. 2013 Mar;66(3):291-4. doi: 10.1016/j.jinf.2012.11.009. Epub 2012 Nov 28.

DOI:10.1016/j.jinf.2012.11.009

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Real-world experience with posaconazole prophylaxis in high-risk hematological patients in Singapore: a prospective audit.新加坡高危血液病患者泊沙康唑预防治疗的真实世界经验：一项前瞻性审计。

J Infect. 2013 Mar;66(3):291-4. doi: 10.1016/j.jinf.2012.11.009. Epub 2012 Nov 28.

2

Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.泊沙康唑片用于造血干细胞移植术后儿科患者抗真菌预防的疗效、安全性及可行性

J Cancer Res Clin Oncol. 2017 Jul;143(7):1281-1292. doi: 10.1007/s00432-017-2369-7. Epub 2017 Mar 3.

3

Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.标准长程泊沙康唑抗真菌预防方案在异基因造血干细胞移植受者中的疗效、安全性和突破性感染。

Biol Blood Marrow Transplant. 2011 Apr;17(4):507-15. doi: 10.1016/j.bbmt.2010.04.017. Epub 2010 May 9.

4

Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.泊沙康唑对血液系统恶性肿瘤中性粒细胞减少患者的预防作用：临床实践中的局限性

Med Mycol. 2014 Oct;52(7):728-35. doi: 10.1093/mmy/myu042. Epub 2014 Jul 10.

5

Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.泊沙康唑治疗药物监测的真实世界研究：单中心经验和文献复习。

Pharmacotherapy. 2013 Oct;33(10):1117-25. doi: 10.1002/phar.1328. Epub 2013 Jul 17.

6

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.口服泊沙康唑在患有移植物抗宿主病的异基因造血干细胞移植受者中的药代动力学。

Pharmacotherapy. 2007 Dec;27(12):1627-36. doi: 10.1592/phco.27.12.1627.

7

Posaconazole: an extended-spectrum triazole antifungal agent.泊沙康唑：一种广谱三唑类抗真菌药。

Clin Ther. 2007 Sep;29(9):1862-86. doi: 10.1016/j.clinthera.2007.09.015.

8

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.分析泊沙康唑作为 12 岁以下异基因造血干细胞移植后患儿的口服抗真菌预防用药。

BMC Infect Dis. 2012 Oct 19;12:263. doi: 10.1186/1471-2334-12-263.

9

Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.血液病或造血干细胞移植患者抗真菌预防药物的比较：系统评价和网络荟萃分析。

JAMA Netw Open. 2020 Oct 1;3(10):e2017652. doi: 10.1001/jamanetworkopen.2020.17652.

10

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.血液系统恶性肿瘤患者和/或接受异基因造血干细胞移植患者静脉注射泊沙康唑的安全性、临床疗效及血药谷浓度：试验外经验

J Antimicrob Chemother. 2016 Dec;71(12):3540-3547. doi: 10.1093/jac/dkw322. Epub 2016 Aug 11.

引用本文的文献

1

Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer center.大型综合性癌症中心血液恶性肿瘤患者的鼻窦肺毛霉菌病季节性聚集。

Antimicrob Resist Infect Control. 2017 Dec 6;6:123. doi: 10.1186/s13756-017-0282-0. eCollection 2017.